Tranexamic acid: Difference between revisions
imported>David E. Volk No edit summary |
imported>David E. Volk No edit summary |
||
| Line 5: | Line 5: | ||
|width=250px | |width=250px | ||
|molname= tranexamic acid | |molname= tranexamic acid | ||
|synonyms= | |synonyms= see below | ||
|molformula= C<sub>8</sub>H<sub>15</sub>NO<sub>2</sub> | |molformula= C<sub>8</sub>H<sub>15</sub>NO<sub>2</sub> | ||
|molmass= 157.2102 | |molmass= 157.2102 | ||
|uses= [[antifibrinolytic]] | |uses= [[antifibrinolytic]] | ||
|properties= | |properties=fibrinogen inhibitor | ||
|hazards= | |hazards= | ||
|iupac=4-(aminomethyl)cyclohexane-1-carboxylic acid | |iupac=4-(aminomethyl)cyclohexane-1-carboxylic acid | ||
|casnumber= 1197-18-8 | |casnumber= 1197-18-8 | ||
| Line 17: | Line 17: | ||
In [[medicine]], [[tranexamic acid]] a hemostatic agent approved for hemorrhaging in [[hemophilia]], with unapproved uses in cyanide poisioning, hereditary [[angioedema]], hyperfibrinolysis induced hemorrhage, postsurgical hemorrhage and prevention of hemorrhage from cardiovascular instability after [[coronary artery bypass graft]]. It is an "inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid." It is similar to, but more potent than [[aminocaproic acid]].<ref name="urlDailyMed: tranexamic acid">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7849 |title=cyklokapron (tranexamic acid) injection, solution |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=U.S. National Library of Medicine |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=2009-02-19}}</ref> It is also used to treat acquired [[angioedema]] due to deficiency of [[complement C1 inhibitor protein]]. | In [[medicine]], [[tranexamic acid]] a hemostatic agent approved for hemorrhaging in [[hemophilia]], with unapproved uses in cyanide poisioning, hereditary [[angioedema]], hyperfibrinolysis induced hemorrhage, postsurgical hemorrhage and prevention of hemorrhage from cardiovascular instability after [[coronary artery bypass graft]]. It is an "inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid." It is similar to, but more potent than [[aminocaproic acid]].<ref name="urlDailyMed: tranexamic acid">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7849 |title=cyklokapron (tranexamic acid) injection, solution |author=Anonymous |authorlink= |coauthors= |date= |format= |work= |publisher=U.S. National Library of Medicine |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=2009-02-19}}</ref> It is also used to treat acquired [[angioedema]] due to deficiency of [[complement C1 inhibitor protein]]. | ||
== Mechanism of Action == | |||
At low concentration, tramexamic acid, which binds to the kringle domain of plasminogen, is a competetive inhibitor of plasminogen activation into [[plasmin]] (fibrinolysin), an [[enzyme]] that degrades [[fibrin]] clots, fibrinogen, and procoagulant plasma proteins such as [[factor V]] and [[factor VIII]]. At higher concentrations it is a noncompetetive inhibitor of plasmin. It binds to the strong and weak receptor sites of plasminogen with affnities about 10 times greater than [[aminocaproic acid]]. | |||
== Synonyms and Trade Names == | == Synonyms and Trade Names == | ||
Revision as of 11:34, 4 July 2009
|
| |||||||
| tranexamic acid | |||||||
| |||||||
| Uses: | antifibrinolytic | ||||||
| Properties: | fibrinogen inhibitor | ||||||
| Hazards: | |||||||
| |||||||
In medicine, tranexamic acid a hemostatic agent approved for hemorrhaging in hemophilia, with unapproved uses in cyanide poisioning, hereditary angioedema, hyperfibrinolysis induced hemorrhage, postsurgical hemorrhage and prevention of hemorrhage from cardiovascular instability after coronary artery bypass graft. It is an "inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid." It is similar to, but more potent than aminocaproic acid.[1] It is also used to treat acquired angioedema due to deficiency of complement C1 inhibitor protein.
Mechanism of Action
At low concentration, tramexamic acid, which binds to the kringle domain of plasminogen, is a competetive inhibitor of plasminogen activation into plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and procoagulant plasma proteins such as factor V and factor VIII. At higher concentrations it is a noncompetetive inhibitor of plasmin. It binds to the strong and weak receptor sites of plasminogen with affnities about 10 times greater than aminocaproic acid.
Synonyms and Trade Names
|
|
References
- ↑ Anonymous. cyklokapron (tranexamic acid) injection, solution. U.S. National Library of Medicine. Retrieved on 2009-02-19.
External links
The most up-to-date information about Tranexamic acid and other drugs can be found at the following sites.
- Tranexamic acid - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Tranexamic acid - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Tranexamic acid - Detailed information from DrugBank.